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Abstract
Palmitoylethanolamide is an endogenous lipid that exerts 
complex vascular effects, enhances the effects of endocan-
nabinoids and induces a direct hypotension, but the mecha-
nisms involved have been poorly explored. Hence, this study 
investigated in Wistar pithed rats the role of CB1, CB2, TRPV1 
and GPR55 receptors in the inhibition by palmitoylethanol-
amide of the vasopressor responses produced by sympa-
thetic stimulation or exogenous noradrenaline. Frequency- 
and dose-dependent vasopressor responses were analysed 
before and during intravenous (i.v.) continuous infusions 
of palmitoylethanolamide in animals receiving i.v. bolus of 
the antagonists NIDA41020 (CB1), AM630 (CB2), capsaze- 
pine (TRPV1), and/or cannabidiol (GPR55). Palmitoyletha-
nolamide (0.1–3.1 μg/kg/min) dose-dependently inhibited 
the sympathetically induced and noradrenaline-induced 
vasopressor responses. Both inhibitions were: (i) partially 
blocked by 100 μg/kg NIDA41020, 100 μg/kg capsazepine, 
or 31 μg/kg cannabidiol; (ii) unaffected by 310 μg/kg AM630; 
and (iii) abolished by the combination NIDA41020 + capsaz-
epine + cannabidiol (100, 100, and 31 μg/kg, respectively). 
The resting blood pressure was decreased by palmitoyletha-
nolamide (effect prevented by NIDA41020, capsazepine or 
cannabidiol, but not by AM630). These results suggest that: 
(i) palmitoylethanolamide inhibits the vasopressor respons-
es to sympathetic stimulation and exogenous noradrenaline 
and that it induces hypotension; and (ii) all these effects are 
mediated by prejunctional and vascular CB1, TRPV1 and 
probably GPR55, but not by CB2, receptors.
© 2020 S. Karger AG, Basel
Introduction
Endogenous cannabinoids and related mediators 
(i.e., endocannabinoids and endocannabinoid-like com-
pounds) play a role in the modulation of a wide variety of 
physiological functions with potential therapeutic use [1–
7]. In cardiovascular homeostasis, they exert actions on 
systemic blood pressure and local blood flow by mecha-
nisms partially elucidated, including: (i) autonomic and 
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sensory neural modulation [8, 9]; (ii) stimulation of en-
dothelial nitric oxide [10]; and (iii) control of smooth 
muscle cell activity [11]. Modulation of vascular tone by 
endocannabinoids involves activation of vascular and 
prejunctional G-protein-coupled receptors (CB1, CB2 
and GPR55), capsaicin receptors (TRPV1) and nuclear 
receptors (PPARα and PPARγ) [8, 9, 12]. The modulation 
of vascular tone by cannabinoids is of such importance 
that they induce prolonged hypotension in the nanomo-
lar range doses [13].
Palmitoylethanolamide is an N-acylethanolamine (a 
fatty acid amide structurally related to the endocannabi-
noid anandamide) that stands out for its capability to 
mimic/potentiate some of the vascular effects induced by 
anandamide, including vasodilatation [14]. Its effects in 
the cardiovascular system have been mainly related to an 
“entourage” action. This “entourage” action may involve, 
among others, an increase in: (i) the levels of other N-
acylethanolamines (and its actions) because palmitoyl-
ethanolamide has more affinity for the main enzyme in-
volved in endocannabinoids degradation (i.e., fatty acid 
amide hydrolase); and (ii) the affinity of other endocan-
nabinoids for their targets [15–17].
Interestingly, palmitoylethanolamide: (i) is present 
in human plasma at 14 pmol/mL [18], and values in the 
picomolar range are also observed in rodents [19]; (ii) is 
detected in several tissues where endocannabinoids 
exert regulatory effects [15–17]; and (iii) displays high 
affinity for (Table 1) and can activate [18] the can- 
nabinoid/lysophospholipid receptor GPR55. As GPR55 
activation results in vasodilatation [8, 10], palmitoyl-
ethanolamide might be involved in the vascular physio-
logical actions of activation of GPR55. Nevertheless, the 
pharmacological nature of the systemic vascular mecha-
nisms by which palmitoylethanolamide induces hypo-
tension and vasorelaxation remains unknown. On this 
basis, the present study in pithed rats was designed in an 
attempt to analyse the effects produced by intravenous 
(i.v.) continuous infusions of palmitoylethanolamide 
on: (i) the vasopressor responses induced by selective 
preganglionic sympathetic stimulation or exogenous 
noradrenaline, and (ii) resting diastolic blood pressure 
(an indicator of total peripheral vascular resistance; 
TPVR). Furthermore, the potential role of CB1, CB2, 
TRPV1, and GPR55 receptors in the above palmitoyl-
ethanolamide effects on diastolic blood pressure was in-
vestigated by using the corresponding selective antago-
nists for these receptors (Table 1). Within this context, 
it is noteworthy that systolic blood pressure is generated 
during heart contraction, and thus it better reflects the 
phenomena in conductance blood vessels [19]. In con-
trast, diastolic blood pressure (which is generated dur-
ing left ventricular relaxation) is directly proportional to 
TPVR [19]; in other words, an increment in TPVR re-
sults in a higher diastolic blood pressure [20].
On the other hand, it is important to highlight that in 
pithed rats the central nervous system has been destroyed. 
Consequently, the autonomic nervous control of visceral 
actions is absent, with only the local and hormonal sys-
tems remaining (e.g., the renin-angiotensin-aldosterone 
system; RAAS). 
Methods
Animals
Healthy male normotensive Wistar rats (250–300 g) were 
maintained under a 12/12-h light-dark cycle (with light beginning 
at 07: 00 h) and kept in a special room at 22 ± 2  ° C and 50% humid-
ity, with food and water ad libitum in their home cages. 
General Methods
Experiments were carried out in 120 rats. After anaesthesia 
with diethyl ether and cannulation of the trachea, the rats were 
pithed by inserting a stainless-steel rod as previously reported [21, 
22]. Immediately afterwards, the animals were artificially venti-
lated with room air using a model 7,025 Ugo Basile pump (56 
strokes/min; stroke volume: 20 mL/kg), as established by Klein-
man and Radford [23]. After bilateral cervical vagotomy, catheters 
were placed in the left and right femoral and jugular veins for: 
(i) the infusion of the agonists by a WPI model sp100i pump 
Table 1. Binding affinity constants (pKi) of several ligands for CB1, 
CB2, TRPV1 and GPR55 receptors, except for α, β and γ, which 
stand for pEC50, PKB and pIC50, respectively, determined in trans-
fected cells
Compound CB1 CB2 TRPV1 GPR55
Agonist
Palmitoylethanolamide <4.5α, a <5.7α, a ND 8.4α, a
Antagonists
NIDA42020 ~8.4b 6.0β, c ND ND
AM630 ~5.2d ~7.5d ND ND
Capsazepine ND ND ~5.8e (r) ND
Cannabidiol ~5.3f ~5.4f ND 6.3γ, a
(r), interaction of anandamide with vanilloid receptors in CHO 
cells transfected with rVR1 (TRPV1) receptors; ND, not 
determined; ~, approximately. 
Data taken from: a Ryberg et al. [46]; b Katoch-Rouse et al. [47]; 
c Donohue et al. [48]; d Ross et al. [49]; e Ross et al. [50]; f Thomas 
et al. [51].
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(World Precision Instruments Inc., Sarasota, FL, USA); and (ii) 
bolus injections of the antagonists or vehicles. The left carotid ar-
tery was connected to a Grass pressure transducer (P23 XL) for the 
recording of blood pressure. Heart rate was measured with a ta-
chograph (7P4, Grass Instrument Co., Quincy, MA, USA) trig-
gered from the blood pressure signal. Both blood pressure and 
heart rate were recorded simultaneously by a model 7 Grass poly-
graph (Grass Instrument Co., Quincy, MA, USA). 
Then, the 120 rats were divided into two main sets, so that the 
effects produced by i.v. continuous infusions of dimethyl sulfoxide 
0.5% (DMSO; vehicle) or palmitoylethanolamide could be inves-
tigated on the vasopressor responses induced by either: (i) selective 
preganglionic (T7–T9) stimulation of the vasopressor sympathetic 
outflow (set 1; n = 80), or (ii) i.v. bolus injections of exogenous 
noradrenaline (set 2; n = 40).
The vasopressor stimulus-response curves (S-R curves) and 
dose-response curves (D-R curves) elicited by sympathetic stimu-
lation and exogenous noradrenaline, respectively, were completed 
in about 30 min. Moreover, the vasopressor sympathetic stimuli 
and the noradrenaline injections were given using a sequential 
schedule, in 0.5 log unit increments at 3- to 5-min intervals. The 
body temperature of each pithed rat was maintained at 37  ° C by a 
lamp and monitored with a rectal thermometer.
Experimental Protocols
After the animals had been in a stable haemodynamic condi-
tion for at least 20 min, baseline values of diastolic blood pressure 
(an indicator of systemic vascular tone) and heart rate were deter-
mined. Subsequently, the following experimental protocols were 
applied.
Electrical Stimulation of the Vasopressor Sympathetic 
Outflow
In the first set of rats (n = 80), the pithing rod was replaced by 
an electrode enamelled except for a 1-cm length 9 cm from the tip, 
so that the uncovered segment was situated at T7–T9 in the spinal 
cord to allow selective preganglionic stimulation of the thoracic 
sympathetic nerves supplying the systemic vasculature (i.e., the 
vasopressor sympathetic outflow); an indifferent electrode was 
placed dorsally [22, 24, 25]. Prior to electrical stimulation, all ani-
mals were pretreated with: (i) gallamine (25 mg/kg, i.v.) to avoid 
electrically induced muscular twitching; and (ii) after 10 min, de-
sipramine (50 µg/kg, i.v.) before each S-R curve to induce higher 
vasopressor responses at low stimulation frequencies, as previous-
ly established [25, 22]. Under these conditions, the vasopressor 
responses to lower stimulation frequencies are greater than those 
elicited without desipramine [22, 25–27]. Ten minutes later, base-
line values of diastolic blood pressure and heart rate were deter-
mined again.
The preganglionic vasopressor sympathetic outflow was then 
stimulated to elicit vasopressor responses by applying 10-s trains 
(2 ms monophasic rectangular pulses, 50 V) at increasing fre-
quencies (0.03, 0.1, 0.3, 1 and 3 Hz) using a sequential schedule, 
as previously described [22, 25–27]. When diastolic blood pres-
sure had returned to baseline levels, the next frequency was ap-
plied. This procedure was performed systematically until the S-R 
curve had been completed (about 30 min). At this point, this set 
of animals was divided into three treatment groups (n = 15, 30 
and 35).
The first group (n = 15) was subdivided into three subgroups 
(n = 5 each) that received an i.v. continuous infusion of: (i) DMSO 
0.5% (vehicle of palmitoylethanolamide, two times; 0.02 mL/min); 
(ii) palmitoylethanolamide (0.1 and 0.31 μg/kg/min), and (iii) pal-
mitoylethanolamide (1 and 3.1 μg/kg/min). Ten minutes later, an 
S-R curve was elicited again during the above infusions to analyse 
their effects on the sympathetically induced vasopressor responses. 
The intervals between the different infusions ranged between 10 
and 15 min, as in each case we waited until the diastolic blood pres-
sure returned to baseline values. 
The second group (n = 30) was subdivided into six subgroups 
(n = 5 each) that received an i.v. bolus injection of: (i) DMSO 2% 
(vehicle of antagonists); (ii) NIDA41020 (100 µg/kg); (iii) AM630 
(310 µg/kg); (iv) capsazepine (100 µg/kg); (v) cannabidiol (31 µg/
kg); and (vi) the combination of 100 µg/kg NIDA41020 + 100 µg/
kg capsazepine + 31 µg/kg cannabidiol. Twenty minutes later, an 
S-R curve was elicited again, as described above, to analyse their ef-
fects per se on the sympathetically induced vasopressor responses.
The third group (n = 35), subdivided into seven subgroups 
(n = 5 each), received an i.v. bolus injection of: (i) 1 mL/kg DMSO 
2%; (ii) 100 µg/kg NIDA41020; (iii) 310 µg/kg AM630; (iv) 31 µg/
kg capsazepine; (v) 100 µg/kg capsazepine; (vi) 31 µg/kg cannabi-
diol; and (vii) the combination of 100 µg/kg NIDA41020 + 100 µg/
kg capsazepine + 31 µg/kg cannabidiol.
Ten minutes later, all subgroups received an i.v. continuous 
infusion of palmitoylethanolamide (3.1 µg/kg/min). After 10 min, 
an S-R curve was constructed again during the infusion of palmi-
toylethanolamide as described above, to analyse the effects of the 
aforementioned compounds on palmitoylethanolamide-induced 
inhibition of the electrically induced vasopressor responses. 
Administration of Exogenous Noradrenaline
The second set of rats (n = 40) was prepared as described above, 
but the pithing rod was left in situ and not replaced by the stimulating 
electrode throughout the experiment (as electrical stimulation was 
not used). After determining baseline values of diastolic blood pres-
sure and heart rate, vasopressor responses were elicited by administer-
ing i.v. bolus injections of exogenous noradrenaline at increasing dos-
es (0.03, 0.1, 0.3, 1 and 3 μg/kg) as previously described [22, 25–27]. 
When diastolic blood pressure had returned to baseline levels, the 
next dose was applied. This procedure was performed until the D-R 
curve had been completed (about 30 min). Subsequently, the animals 
were divided into two groups (n = 10 and 30, respectively).
The first group (n = 10) was subdivided into two subgroups 
(n = 5 each) that, respectively, received i.v. continuous infusions 
of: (i) DMSO 0.5% (two times; 0.02 mL/min), and (ii) palmitoyl-
ethanolamide (1 and 3.1 μg/kg/min). Ten minutes after starting 
these infusions, a D-R curve for noradrenaline was elicited again.
The second group (n = 30) was subdivided into six subgroups 
(n = 5 each) that received an i.v. bolus injection of: (i) 1 mL/ 
kg DMSO 2%; (ii) 100 µg/kg NIDA41020; (iii) 310 µg/kg AM630; 
(iv) 100 µg/kg capsazepine; (v) 31 µg/kg cannabidiol; and (vi) the 
combination of 100 µg/kg NIDA41020 + 100 µg/kg capsazepine + 
31 µg/kg cannabidiol.
Ten minutes later, all subgroups received an i.v. continuous 
infusion of palmitoylethanolamide (3.1 µg/kg/min). After 10 min, 
a D-R curve for noradrenaline was elicited again to analyse the ef-
fects of the aforementioned compounds on palmitoylethanol-
amide-induced inhibition of the vasopressor responses induced by 
noradrenaline. 
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Drugs
Apart from the anaesthetic (diethyl ether), the compounds 
used in this study (obtained from the sources indicated) were: 
gallamine triethiodide, desipramine hydrochloride, (–)-nor- 
adrenaline bitartrate, palmitoylethanolamide, capsazepine and 
NIDA41020 (1-[2,4-dichlorophenyl]-5-[4-methoxyphenyl]-4- 
methyl-N-[1-piperidinyl]-1H-pyrazole-3-carboxamide; Sigma 
Chemical Co., St Louis, MO, USA); AM630 (6-iodo-2-methyl-
1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl(4-methoxyphenyl)
methanone; Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA), and cannabidiol (TOCRIS, Avonmouth, UK).
The compounds were dissolved as follows: (i) palmitoyletha-
nolamide in DMSO 0.5%; (ii) gallamine, desipramine, and nor-
adrenaline in physiological saline, and (iii) NIDA41020, AM630, 
capsazepine and cannabidiol in DMSO 2%. The resulting solutions 
were gauged with physiological saline. In the case of noradrena-
line, ascorbic acid 1% was used to prevent oxidation. These vehi-
cles had no effect on baseline diastolic blood pressure or heart rate 
(not shown). Fresh solutions were prepared for each experiment. 
The doses mentioned in the text refer to the free base of substanc-
es, except in the case of gallamine and desipramine, where they 
refer to their corresponding salts.
Data Presentation and Statistical Analysis
All data in the text and figures are presented as means ± SEM. 
It must be emphasised that the data and statistical analysis used 
in the present study comply with recent recommendations on 
experimental design and analysis in pharmacology, including 
that data subjected to statistical analysis should have a minimum 
of n = 5 independent samples/individuals per group [28]. The 
peak changes in diastolic blood pressure by electrical stimula-
tion or exogenous noradrenaline in saline- and agonist-infused 
animals were determined. The difference between the changes 
in diastolic blood pressure within one subgroup of animals was 
evaluated by the Student-Newman-Keuls post hoc test, once a 
two-way repeated measures analysis of variance (randomised 
block design) had revealed that the samples represented differ-
ent populations [29]. Statistical significance was accepted at p < 
0.05. 
Results
Systemic Haemodynamic Variables
The baseline values of diastolic blood pressure and 
heart rate in the 120 rats were 54 ± 7 mm Hg and 296 ± 
13 beats/min, respectively. The i.v. administration of de-
sipramine (50 µg/kg) produced a transient increase of 
both variables (not shown), but baseline values recov-
ered after 5 min (p > 0.05), as previously reported [22, 
25–27]. The latter baseline values in desipramine-pre-
treated rats were not significantly modified during the 
continuous infusions of: (1) DMSO 0.5% (control, two 
times, 0.02 mL/min; Table 2), and (ii) palmitoylethanol-
amide (0.1–0.3 μg/kg/min; Table 2). In contrast, the 
baseline values of diastolic blood pressure were signifi-
cantly decreased by the continuous infusions of palmi-
toylethanolamide (1–3.1 µg/kg/min; Table 2). Further-
more, the diastolic blood pressure values (in the absence 
of agonists) were not modified (p > 0.05) after i.v. bolus 
injections of: (i) 31 and 100 µg/kg NIDA41020; (ii) 310 
µg/kg AM630; (iii) 31–100 µg/kg capsazepine; (iv) 31 
µg/kg cannabidiol; or (v) the combination of 100 µg/kg 
NIDA41020 + 100 µg/kg capsazepine + 31 µg/kg canna-
bidiol (data not shown).
Table 2. Effects of the different i.v. continuous infusions of com-
pounds (n = 5 each) on the basal values of diastolic blood pressure 
determined 10 min after a stable condition with no treatment (ba-
sal) or 10 min after each corresponding infusion had commenced
Treatment Diastolic blood pressure, mm Hg
basal after 1st  
dose 
treatment
after 2nd 
dose 
treatment
DMSO 0.5% (0.02 mL/min; 
given twice) 49±8 53±5 51±2
Palmitoylethanolamide 
(0.1 and 0.31 μg/kg/min) 59±6 54±5 51±6
Palmitoylethanolamide 
(1 and 3.1 μg/kg/min) 54±7 48±6a 42±5a
All values are expressed as the mean ± SEM. a p < 0.05 versus 
the corresponding basal value. DMSO, dimethyl sulfoxide.
Table 3. Effect of the different i.v. bolus injections of compounds 
(i.e., before starting the infusion of palmitoylethanolamide) on the 
hypotension induced by 3.1 μg/kg/min palmitoylethanolamide
Pretreatment Diastolic blood pressure, mm Hg
basal palmitoylethanolamide
DMSO 0.5%, 1 mL/kg 60±5 41±4a
DMSO 2%, 1 mL/kg 60±3 43±2a
NIDA41020, 100 μg/kg 50±7 46±9
AM630, 310 μg/kg 50±4 40±4a
Capsazepine, 31 μg/kg 57±9 49±9
Capsazepine, 100 μg/kg 51±6 46±7
Cannabidiol, 31 μg/kg 52±11 44±9
Combinationb 64±9 63±3
All values are expressed as the mean ± SEM. The basal values 
shown in this table correspond to those obtained 10 min after ad-
ministering the above compounds. a  p < 0.05 versus the corre-
sponding basal value. b Combination of 100 μg/kg NIDA41020 + 
100 μg/kg capsazepine + 31 μg/kg cannabidiol. 
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Effect of the Antagonists on the Hypotensive Responses 
Produced by Palmitoylethanolamide
As shown in Table 3, the hypotensive responses induced 
by 3.1 µg/kg/min palmitoylethanolamide: (i) remained un-
altered after DMSO (0.5 and 2%) or 310 µg/kg AM630, and 
(ii) were abolished by 100 µg/kg of NIDA41020, 31 or 100 
µg/kg of capsazepine, 31 µg/kg of cannabidiol or the com-
bination 100 µg/kg of NIDA41020 + 100 µg/kg of capsaze-
pine + 31 µg/kg of cannabidiol. 
Initial Effects Produced by Electrical Sympathetic 
Stimulation or Exogenous Noradrenaline on Diastolic 
Blood Pressure and Heart Rate
The increases in diastolic blood pressure induced by 
electrical stimulation of the sympathetic vasopressor out-
flow (0.03–3 Hz) or by exogenous noradrenaline (0.03–3 
μg/kg) were immediate, frequency-dependent (sympa-
thetic stimulation), or dose-dependent (exogenous nor-
adrenaline; see control responses in Fig. 1–5). As previ-
ously described [29, 30], i.v. bolus injections of noradren-
aline also produced dose-dependent and transient 
increases in heart rate (not shown). The vasopressor re-
sponses to either electrical stimulation or noradrenaline 
were significant when compared with their correspond-
ing baseline values (not shown). The electrically induced 
vasopressor responses are induced by selective sympa-
thetic stimulation, as only negligible changes in heart rate 
were observed, as previously reported by our group [5, 29, 
31].
Effect of i.v. Continuous Infusions of Vehicle or 
Palmitoylethanolamide on the Vasopressor Responses 
Induced by Either Sympathetic Stimulation or 
Exogenous Noradrenaline
Figure 1 shows the vasopressor responses induced by 
electrical stimulation before (control) and during the i.v. 
continuous infusion of DMSO 0.5% (0.02 mL/min; 2 
times) and palmitoylethanolamide (0.1, 0.3, 1, and 3.1 µg/
kg/min). In animals infused with DMSO 0.5%, the electri-
cally induced vasopressor responses remained essentially 
unchanged (p > 0.05) when repeating two subsequent S-R 
curves (Fig. 1a). In contrast, the infusions of palmitoyl-
ethanolamide (0.1–3.1 µg/kg/min) produced a significant 
inhibition of the electrically induced vasopressor re-
sponses (Fig. 1b, c).
Moreover, Figure 2 shows the vasopressor responses 
induced by i.v. injections of noradrenaline before (con-
trol) and during i.v. continuous infusions of DMSO or 
palmitoylethanolamide. In animals infused with DMSO 
0.5% (0.02 mL/min), the vasopressor responses to nor-
adrenaline remained unchanged when repeating two 
subsequent D-R curves (Fig.  2a). In contrast, the infu-
sions of 1 and 3.1 µg/kg/min palmitoylethanolamide pro-
duced a dose-dependent inhibition of the vasopressor re-
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Control
DMSO 0.5%
 1st (0.02 mL/min)
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Control
Palmitoylethanolamide
 0.1 µg/kg/min
 0.31 µg/kg/min
Control
Palmitoylethanolamide
 1 µg/kg/min
 3.1 µg/kg/min
a b c
Fig. 1. Effect of an i.v. infusion (n = 5 for each figure) of: DMSO 0.5% (0.02 mL/min; twice; a) and palmitoyle-
thanolamide (0.1–3.1 µg/kg/min; b, c) in the presence of desipramine (50 µg/kg, i.v.) on the vasopressor respons-
es induced by electrical stimulation of the preganglionic (T7–T9) sympathetic outflow in pithed rats. Empty sym-
bols depict either control responses (⚪) or non-significant (p > 0.05) responses (△, ◻) versus the control. Solid 
symbols (▲, ◼) represent significantly different responses (p < 0.05) versus the control.
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sponses. Indeed, 3.1 µg/kg/min palmitoylethanolamide 
produced the highest inhibition of the vasopressor re-
sponses induced by either electrical stimulation (Fig. 1c) 
or i.v. noradrenaline (Fig. 2b). For this reason, 3.1 µg/kg/
min of palmitoylethanolamide was chosen for further 
pharmacological analysis (see below).
Effect per se of Vehicles or Antagonists on the 
Vasopressor Responses by Electrical Stimulation
Figure 3 shows that the electrically induced vasopres-
sor responses remained unchanged (as compared with 
the control S-R curves; p > 0.05) after an i.v. bolus injec-
tion of: (i) 1 mL/kg DMSO 2% (Fig. 3a); (ii) 100 μg/kg 
NIDA41020 (Fig.  3b); (iii) 310 μg/kg AM630 (Fig.  3c); 
(iv) 31 μg/kg cannabidiol (Fig. 3d); (v) 100 μg/kg capsaz-
epine (Fig.  3e); and (vi) the combination 100 μg/kg 
NIDA41020 + 100 μg/kg capsazepine + 31 μg/kg canna-
bidiol (Fig. 3f). 
Effect of Vehicles or Antagonists on 
Palmitoylethanolamide-Induced Inhibition of the 
Vasopressor Responses to Sympathetic Electrical 
Stimulation
Figure 4 shows that the sympathoinhibition produced 
by 3.1 µg/kg/min palmitoylethanolamide was: (i) unaltered 
after 1 mL/kg of DMSO 0.5% (Fig. 4a) or 310 µg/kg AM630 
(Fig. 4c); (ii) partially blocked by 100 µg/kg of NIDA42020 
(Fig. 4b), 31 and 100 µg/kg of capsazepine (Fig. 4d, e) or 
31 µg/kg of cannabidiol (Fig. 4f); and (iii) abolished by the 
combination 100 µg/kg NIDA42020 + 100 µg/kg capsaze-
pine + 31 µg/kg cannabidiol (Fig. 4g).
Effect of Vehicles or Antagonists on 
Palmitoylethanolamide-Induced Inhibition of the 
Vasopressor Responses to Exogenous Noradrenaline 
As illustrated in Figure 5, the inhibition of the vaso-
pressor responses to noradrenaline by 3.1 µg/kg/min 
palmitoylethanolamide was: (i) unaltered after 1 mL/ 
kg DMSO 0.5% (Fig. 5a) or 310 µg/kg AM630 (Fig. 5c); 
(ii) partially blocked by 100 µg/kg NIDA42020 (Fig. 5b), 
100 µg/kg capsazepine (Fig. 5d), or 31 µg/kg cannabidiol 
(Fig. 5e); and (iii) abolished by the combination 100 µg/
kg NIDA42020 + 100 µg/kg capsazepine + 31 µg/kg can-
nabidiol (Fig. 5f).
Discussion
General
Palmitoylethanolamide has emerged as an interesting 
molecule with several potential therapeutic uses (e.g., in 
the treatment of neuropathic pain [32]). At the cardiovas-
cular level, palmitoylethanolamide is known to boost the 
effects of classic endocannabinoids such as anandamide, 
but its potential direct role in the vascular system remains 
unclear [14]. Indeed, anandamide and analogues exert 
complex triphasic effects on blood pressure [33], which 
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Fig. 2. Effect of an i.v. infusion (n = 5 for 
each figure) of: DMSO 0.5% (0.02 mL/min, 
twice; a) and palmitoylethanolamide (1 
and 3.1 µg/kg/min; b) on the vasopressor 
responses induced by exogenous nor-
adrenaline in pithed rats. Empty symbols 
depict either control responses (⚪) or non-
significant (p > 0.05) responses (△, ◻) ver-
sus the control. Solid symbols (▲, ◼) rep-
resent significantly different responses (p < 
0.05) versus the control. * represents a sig-
nificantly different response (p < 0.05) be-
tween palmitoylethanolamide 1 µg/kg/min 
versus 3.1 µg/kg/min.
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basically consist of: (i) a quick transitory decrease in dia-
stolic blood pressure; (ii) a rapid increase in diastolic 
blood pressure; and (iii) a long-lasting hypotension. Ac-
cordingly, this study has made an attempt to identify the 
pharmacological profile of the palmitoylethanolamide 
sensitive-receptors mediating inhibition of the vasopres-
sor responses induced by sympathetic stimulation or ex-
ogenous noradrenaline. Apart from the implications dis-
cussed below and recognising the complex pharmacolog-
ical properties of the majority of the compounds used 
(Table 1), the present study shows that, in addition to the 
hypotension induced by palmitoylethanolamide, this 
compound inhibits the vasopressor responses induced by 
electrical sympathetic stimulation and exogenous nor-
adrenaline. In all cases, the receptors involved resemble 
the pharmacological profile of CB1, TRPV1 and GPR55 
receptors, but not of CB2 receptors. Together, these find-
ings shed further light on the potential role of palmitoyl-
ethanolamide for modulating per se the systemic vascular 
tone (i.e., the vasopressor responses to sympathetic stim-
ulation and exogenous noradrenaline) and not only as an 
“entourage” compound. 
It is important to note that all antagonists (used at dos-
es high enough to completely block their respective re-
ceptors in pithed rats [8, 9]) failed to modify per se the 
baseline diastolic blood pressure and heart rate. There-
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fore, any effect of a given antagonist on the vasopressor 
sympathoinhibition can be attributed to a direct interac-
tion of the antagonist with its respective receptors on the 
vasopressor sympathetic nerves and not to physiological 
antagonism.
Changes on Systemic Haemodynamic Variables 
Produced by the Different Treatments
A remarkable finding of our study was the capability 
of 1 and 3.1 µg/kg/min palmitoylethanolamide to pro-
duce hypotension in pithed rats (which typically have a 
low baseline diastolic blood pressure as the central ner-
vous system is not operative; Table 2), and that this re-
sponse was blocked by pretreatment with NIDA41020, 
capsazepine or cannabidiol, but not by AM630 (Table 3). 
The simplest interpretation of these findings would be 
that palmitoylethanolamide-induced hypotension in-
volves the activation of CB1, TRPV1 and GPR55, but not 
CB2, receptors. Nevertheless, palmitoylethanolamide is 
capable of inducing vasorelaxation by the activation of 
receptor-dependent and independent mechanisms on 
vascular smooth muscle [14, 31].
Admittedly, one limitation of the present study is that 
our results do not allow us to discriminate between direct 
versus indirect actions induced by palmitoylethanol-
amide. In this respect, one possibility that this study did 
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not explore is the potential interference of palmitoyletha-
nolamide with the RAAS, in view that in pithed rats a 
proportion of blood pressure seems to be maintained by 
activation of the RAAS, as reported by Schlicker et al. 
[30]. Consistent with this possibility, infusions of angio-
tensin II produce tachycardic and vasopressor responses 
[33, 34]. Clearly, this is a hypothetical speculation that 
requires other experimental approaches that include the 
use of i.v. bolus injections of palmitoylethanolamide in 
pithed rats whose low resting blood pressure is restored 
by an i.v. continuous infusion of a vasoconstrictor agent 
(with the RAAS pharmacological approach implemented 
by Schlicker et al. [30]). 
Possible Mechanisms Involved in the Inhibition by 
Palmitoylethanolamide of the Vasopressor Responses 
Induced by Sympathetic Stimulation or Exogenous 
Noradrenaline
Our results show that the vasopressor responses in-
duced by electrical sympathetic stimulation and exoge-
nous noradrenaline were dose-dependently inhibited by 
palmitoylethanolamide. These inhibitory responses can-
not be attributed to tachyphylaxis as the control respons-
es remained unchanged after vehicle (Fig. 1a, 2a). An ad-
ditional fact drawn from this finding is that no time-de-
pendent changes occurred in our experiments. Moreover, 
it is worth emphasising that we did not measure electri-
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cally induced perivascular sympathetic nerve activity di-
rectly, but the electrically induced neurotransmitter re-
lease in the systemic vasculature could be estimated indi-
rectly by measurement of the evoked vasopressor 
response. In this respect, it may be noted that there was 
some degree of variability in the control vasopressor re-
sponses of the different (sub)groups (Fig. 1–5), as simi-
larly observed in other studies [25, 22, 26, 27]. This is 
most likely due to individual differences in each animal, 
but this biological variability certainly has no bearing on 
the results obtained with the different compounds, as 
each effect was analysed within the same group of ani-
mals, as previously reported [22, 25–27]. 
The inhibition of the vasopressor responses by sympa-
thetic stimulation seems to be predominantly mediated 
by TRPV1 receptors, as capsazepine induced a more pro-
nounced blockade of these responses (Fig.  4e) as com-
pared to that produced for the vasopressor responses to 
exogenous noradrenaline (Fig. 5d). These results suggest 
that TRPV1 receptors may be mainly located prejunc-
tionally (i.e., on perivascular sympathetic neurons). As 
TRPV1 receptors are cationic channels related with the 
excitation and transmission of action potentials, its activ-
ity on sympathetic nerves would result in noradrenaline 
release rather than inhibition. Interestingly, activation of 
prejunctional TRPV1 receptors on sensory CGRPergic 
perivascular fibres is classically associated with CGRP re-
lease and vasodilatation [35]. Moreover, it has been re-
ported that palmitoylethanolamide activates TRPV1 
channels [36]; on the other hand, part of its entourage 
effect is mediated via TRPV1 [14]. Thus, one possibility 
for explaining the inhibition by palmitoylethanolamide 
sensitive to capsazepine is by its possible inhibition of 
CGRP release from perivascular sensory CGRPergic 
nerves. Clearly, this speculation needs to be further inves-
tigated with additional experiments that fall beyond the 
scope of the present study. 
It is important to highlight that NIDA141020 (a CB1 
receptor antagonist) and cannabidiol (a GPR55 antago-
nist with other complex pharmacological properties) in-
duced a slight blockade of the inhibition by palmitoyl-
ethanolamide on the sympathetic vasopressor responses 
(Fig. 4b, f, respectively). This blockade suggests the in-
volvement of CB1 and GPR55 receptors, respectively. In-
deed, CB1 receptors have been associated with the inhibi-
tion of noradrenaline release in the systemic vasculature 
of pithed rats [8]. However, as the affinity of palmitoyl-
ethanolamide for CB1 receptors is rather low (Table 1), it 
is possible that this effect is also induced by the entourage 
effect classically described for palmitoylethanolamide 
rather than a direct interaction [37]. Finally, the partial 
blockade by cannabidiol (GPR55 antagonist; Table 1) of 
the inhibition induced by palmitoylethanolamide on the 
vasopressor responses is probably mediated by endothe-
lial GPR55 receptors, which have been reported to induce 
vasodilatation [8, 10]. 
In the case of the vasopressor responses induced by 
exogenous noradrenaline, the antagonists NIDA16020046 
(CB1), capsazepine (TRPV1), and cannabidiol (GPR55), 
but not AM630 (CB2), induced a partial blockade of the 
inhibition induced by palmitoylethanolamide when giv-
en separately. These results suggest that the inhibition of 
noradrenaline-induced vasopressor responses involves 
the sum of a combination of effects mediated by CB1, 
TRPV1, and GPR55 receptors. This idea is further sup-
ported by the fact that only the combination of CB1, 
TRPV1 and GPR55 antagonists could abolish this vaso-
pressor response (Fig.  5f). The same pharmacological 
profile was observed in the sympathetic vasopressor re-
sponses (Fig.  4g). Similar results have been reported 
where palmitoylethanolamide induces its effects via a 
complex interaction with CB1, CB2, TRPV1, GPR55 and 
PPAR receptors and channels [38].
Potential Clinical Implications for the Use of 
Palmitoylethanolamide
Palmitoylethanolamide is commercially available and 
has recently been suggested for therapeutic use as an anti-
inflammatory agent and against retinopathy [39]. Its 
chronic use has also been suggested to increase the qual-
ity of life in patients with certain types of pain [40] and to 
decrease pain symptoms in patients with fibromyalgia 
[41]. Nevertheless, these studies seem to be devoid of a 
careful analysis on the potential side effects, particularly 
the cardiovascular consequences of the use of palmitoyl-
ethanolamide. Our results in pithed rats, an experimental 
model predictive of systemic cardiovascular side effects 
[42] that cannot be obtained from in vitro studies [43], 
suggest that palmitoylethanolamide produces hypoten-
sion and an attenuation of the sympathetic vasopressor 
outflow. These potential vascular side effects should be 
considered in future clinical studies analysing the thera-
peutic uses of palmitoylethanolamide. 
Conclusion
Taken together, our results suggest that palmitoyletha-
nolamide induced hypotension and an inhibition of the 
noradrenergic vasopressor responses via complex inter-
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actions that involve CB1 (sympathetic), TRPV1 (sensory) 
and GPR55 (endothelial) receptors. Hence, it seems very 
likely that the functional activation of these prejunctional 
and endothelial receptors by palmitoylethanolamide 
would explain, at least in part, the hypotension produced 
by this compound.
Acknowledgements
The authors would like to thank Mr. Mauricio Villasana and 
Engr. José Rodolfo Fernández-Calderón for their assistance. 
Statement of Ethics
All experimental protocols in this study were approved by our 
Institutional Ethics Committee (CICUAL-Cinvestav; permission 
protocol No. 507-12) in accordance with the guide for the Care and 
Use of Laboratory Animals in the USA [44] and with the ARRIVE 
guidelines [45].
Disclosure Statement
All authors declare that they have no competing interests.
Funding Sources
Prof. Carlos M. Villalón was financially supported by the SEP-
Cinvestav Research Support Fund (grant No. 50). Dr. Bruno A. 
Marichal Cancino was financially supported by “Dirección Gen-
eral de Investigación y Posgrado” from Autonomous University of 
Aguascalientes (grant PIBB19-1).
Author Contributions
B.A.M.-C. performed the experiments and participated in the 
design of the study with C.M.V.; E.R.-S.J. and B.A.M.-C. per-
formed the data analysis and produced the graphs. A.M., A.G.-H., 
C.M.V., and B.A.M.-C. participated in the data interpretation and 
writing of the manuscript. All authors read and approved the final 
manuscript.
References
 1 Marichal-Cancino BA, Sánchez-Fuentes A, 
Méndez-Díaz M, Ruiz-Contreras AE, Pros-
péro-García O. Blockade of GPR55 in the dor-
solateral striatum impairs performance of rats 
in a T-maze paradigm. Behav Pharmacol. 
2016 Jun; 27(4): 393–6.
 2 Sánchez-Fuentes A, Marichal-Cancino BA, 
Méndez-Díaz M, Becerril-Meléndez AL, 
Ruiz-Contreras AE, Prospéro-Garcia O. 
mGluR1/5 activation in the lateral hypothala-
mus increases food intake via the endocan-
nabinoid system. Neurosci Lett. 2016 Sep; 631: 
104–8.
 3 Marichal-Cancino BA, Fajardo-Valdez A, 
Ruiz-Contreras AE, Mendez-Díaz M, Prospe-
ro-García O. Advances in the Physiology of 
GPR55 in the Central Nervous System. Curr 
Neuropharmacol. 2017; 15(5): 771–8.
 4 Rosenberg EC, Patra PH, Whalley BJ. Thera-
peutic effects of cannabinoids in animal mod-
els of seizures, epilepsy, epileptogenesis, and 
epilepsy-related neuroprotection. Epilepsy 
Behav. 2017 May; 70(Pt B): 319–27. https://
doi.org/10.1016/j.yebeh.2016.11.006.
 5 Guerrero-Alba R, Barragán-Iglesias P, 
González-Hernández A, Valdez-Moráles EE, 
Granados-Soto V, Condés-Lara M, et al. 
Some prospective alternatives for treating 
pain: the endocannabinoid system and its pu-
tative receptors GPR18 and GPR55. Front 
Pharmacol. 2019 Jan; 9: 1496.
 6 Marichal-Cancino BA, Fajardo-Valdez A, 
Ruiz-Contreras AE, Méndez-Díaz M, Pros-
péro-García O. Possible role of hippocampal 
GPR55 in spatial learning and memory in 
rats. Acta Neurobiol Exp (Warsz). 2018; 78(1): 
41–50.
 7 Ramírez-Orozco RE, García-Ruiz R, Morales 
P, Villalón CM, Villafán-Bernal JR, Marichal-
Cancino BA. Potential metabolic and behav-
ioural roles of the putative endocannabinoid 
receptors GPR18, GPR55 and GPR119 in 
feeding. Curr Neuropharmacol. 2019; 17(10): 
947–60.
 8 Marichal-Cancino BA, Manrique-Maldona-
do G, Altamirano-Espinoza AH, Ruiz-Salinas 
I, González-Hernández A, Maassenvanden-
brink A, et al. Analysis of anandamide- and 
lysophosphatidylinositol-induced inhibition 
of the vasopressor responses produced by 
sympathetic stimulation or noradrenaline in 
pithed rats. Eur J Pharmacol. 2013 Dec; 721(1-
3): 168–77.
 9 Marichal-Cancino BA, Altamirano-Espinoza 
AH, Manrique-Maldonado G, MaassenVan-
DenBrink A, Villalón CM. Role of pre-junc-
tional CB1, but not CB2, TRPV1 or GPR55 
receptors in anandamide-induced inhibition 
of the vasodepressor sensory CGRPergic out-
flow in pithed rats. Basic Clin Pharmacol Tox-
icol. 2014 Mar; 114(3): 240–7.
10 AlSuleimani YM, Hiley CR. The GPR55 ago-
nist lysophosphatidylinositol relaxes rat mes-
enteric resistance artery and induces Ca(2+) 
release in rat mesenteric artery endothelial 
cells. Br J Pharmacol. 2015 Jun; 172(12): 3043–
57.
11 Malinowska B, Baranowska-Kuczko M, 
Schlicker E. Triphasic blood pressure re-
sponses to cannabinoids: do we understand 
the mechanism? Br J Pharmacol. 2012 Apr; 
165(7): 2073–88.
12 O’Sullivan SE, Kendall DA, Randall MD. 
Time-dependent vascular effects of endocan-
nabinoids mediated by peroxisome prolifera-
tor-activated receptor gamma (PPARγ). 
PPAR Res. 2009; 2009: 425289.
13 Zakrzeska A, Schlicker E, Baranowska M, 
Kozłowska H, Kwolek G, Malinowska B. A 
cannabinoid receptor, sensitive to O-1918, is 
involved in the delayed hypotension induced 
by anandamide in anaesthetized rats. Br J 
Pharmacol. 2010 Jun; 160(3): 574–84.
14 Ho WS, Barrett DA, Randall MD. ‘Entourage’ 
effects of N-palmitoylethanolamide and N-
oleoylethanolamide on vasorelaxation to 
anandamide occur through TRPV1 receptors. 
Br J Pharmacol. 2008 Nov; 155(6): 837–46.
15 Richardson D, Ortori CA, Chapman V, Ken-
dall DA, Barrett DA. Quantitative profiling of 
endocannabinoids and related compounds in 
rat brain using liquid chromatography-tan-
dem electrospray ionization mass spectrom-
etry. Anal Biochem. 2007 Jan; 360(2): 216–26.
16 Balvers MG, Verhoeckx KC, Meijerink J, 
Wortelboer HM, Witkamp RF. Measurement 
of palmitoylethanolamide and other N-acyle-
thanolamines during physiological and path-
ological conditions. CNS Neurol Disord Drug 
Targets. 2013 Feb; 12(1): 23–33.
17 Petrosino S, Schiano Moriello A, Cerrato S, 
Fusco M, Puigdemont A, De Petrocellis L, et 
al. The anti-inflammatory mediator palmi-
toylethanolamide enhances the levels of 2-ar-
achidonoyl-glycerol and potentiates its ac-
tions at TRPV1 cation channels. Br J Pharma-
col. 2016 Apr; 173(7): 1154–62.
18 Godlewski G, Offertáler L, Wagner JA, Kunos 
G. Receptors for acylethanolamides-GPR55 
and GPR119. Prostaglandins Other Lipid Me-
diat. 2009 Sep; 89(3-4): 105–11.
D
ow
nl
oa
de
d 
by
: 
Er
as
m
us
 U
ni
ve
rs
ity
 R
ot
te
rd
am
15
4.
59
.1
24
.3
8 
- 4
/2
9/
20
20
 1
0:
43
:5
0 
AM
Marichal-Cancino et al.J Vasc Res12
DOI: 10.1159/000506158
19 Chaudhry RR. Physiology, cardiovascular. In: 
StatPearls. Treasure Island: StatPearls; 2019. 
Available from: https://www.ncbi.nlm.nih.
gov/books/NBK493197/
20 de Simone G, Pasanisi F. Systolic, diastolic 
and pulse pressure: pathophysiology. Ital 
Heart J Suppl. 2001 Apr; 2(4): 359–62. Italian.
21 Shipley RE, Tilden JH. A pithed rat prepara-
tion suitable for assaying pressor substances. 
Proceedings of the Society for Experimental 
Biology and Medicine Society for Experimen-
tal Biology and Medicine (New York, NY). 
1947 Apr; 64(4): 453-5.
22 Villalón CM, Centurión D, Rabelo G, de Vries 
P, Saxena PR, Sánchez-López A. The 5-HT1-
like receptors mediating inhibition of sympa-
thetic vasopressor outflow in the pithed rat: 
operational correlation with the 5-HT1A, 
5-HT1B and 5-HT1D subtypes. Br J Pharma-
col. 1998 Jul; 124(5): 1001–11.
23 Kleinman LI, Radford EP Jr. Ventilation stan-
dards for small mammals. J Appl Physiol. 
1964 Mar; 19(2): 360–2.
24 Gillespie JS, Maclaren A, Pollock D. A meth-
od of stimulating different segments of the au-
tonomic outflow from the spinal column to 
various organs in the pithed cat and rat. Br J 
Pharmacol. 1970 Oct; 40(2): 257–67.
25 Villalón CM, Contreras J, Ramŕiez-San Juan 
E, Castillo C, Perusquía M, López-Muñoz FJ, 
et al. 5-hydroxytryptamine inhibits pressor 
responses to preganglionic sympathetic nerve 
stimulation in pithed rats. Life Sci. 1995; 
57(8): 803–12.
26 Ruiz-Salinas I, González-Hernández A, Man-
rique-Maldonado G, Marichal-Cancino BA, 
Altamirano-Espinoza AH, Villalón CM. Pre-
dominant role of the dopamine D3 receptor 
subtype for mediating the quinpirole-induced 
inhibition of the vasopressor sympathetic 
outflow in pithed rats. Naunyn Schmiede-
bergs Arch Pharmacol. 2013 May; 386(5): 
393–403.
27 Ruiz-Salinas I, Rocha L, Marichal-Cancino 
BA, Villalón CM. Cardiovascular Alterations 
during the Interictal Period in Awake and 
Pithed Amygdala-Kindled Rats. Basic Clin 
Pharmacol Toxicol. 2016 Aug; 119(2): 165–72.
28 Curtis MJ, Bond RA, Spina D, Ahluwalia A, 
Alexander SP, Giembycz MA, et al. Experi-
mental design and analysis and their report-
ing: new guidance for publication in BJP. Br J 
Pharmacol. 2015 Jul; 172(14): 3461–71.
29 Steel RG. Principles and procedures of statis-
tics, a biomedical approach.2nd ed. Tokyo: 
Kogakushao; 1980.
30 Schlicker E, Erkens K, Göthert M. Probable 
involvement of vascular angiotensin II forma-
tion in the beta 2-adrenoceptor-mediated fa-
cilitation of the neurogenic vasopressor re-
sponse in the pithed rat. Naunyn Schmiede-
bergs Arch Pharmacol. 1988 Nov; 338(5): 
536–42.
31 White R, Hiley CR. The actions of some can-
nabinoid receptor ligands in the rat isolated 
mesenteric artery. Br J Pharmacol. 1998 Oct; 
125(3): 533–41.
32 Hesselink JM, Hekker TA. Therapeutic utility 
of palmitoylethanolamide in the treatment of 
neuropathic pain associated with various 
pathological conditions: a case series. J Pain 
Res. 2012; 5: 437–42.
33 Knape JTA, van Zwieten PA. Positive chrono-
tropic activity of angiotensin II in the pithed 
normotensive rat is primarily due to activa-
tion of cardiac β1-adrenoceptors. Naunyn-
Schmiedebergs Arch Pharmacol. 1988; 338(2): 
185–90. https://doi.org/10.1007/BF00174868.
34 Zhang J, Pfaffendorf M, van Zwieten PA. Pos-
itive inotropic action of angiotensin II in the 
pithed rat. Naunyn Schmiedebergs Arch 
Pharmacol. 1993 Jun; 347(6): 658–63.
35 Marichal-Cancino BA, González-Hernández 
A, Manrique-Maldonado G, Ruiz-Salinas II, 
Altamirano-Espinoza AH, MaassenVanDen-
Brink A, et al. Intrathecal dihydroergotamine 
inhibits capsaicin-induced vasodilatation in 
the canine external carotid circulation via 
GR127935- and rauwolscine-sensitive recep-
tors. Eur J Pharmacol. 2012 Oct; 692(1-3): 69–
77.
36 Ambrosino P, Soldovieri MV, Russo C, Tagli-
alatela M. Activation and desensitization of 
TRPV1 channels in sensory neurons by the 
PPARα agonist palmitoylethanolamide. Br J 
Pharmacol. 2013 Mar; 168(6): 1430–44.
37 García MC, Adler-Graschinsky E, Celuch SM. 
Enhancement of the hypotensive effects of in-
trathecally injected endocannabinoids by the 
entourage compound palmitoylethanol-
amide. Eur J Pharmacol. 2009 May; 610(1-3): 
75–80.
38 Borrelli F, Romano B, Petrosino S, Pagano E, 
Capasso R, Coppola D, et al. Palmitoyletha-
nolamide, a naturally occurring lipid, is an 
orally effective intestinal anti-inflammatory 
agent. Br J Pharmacol. 2015 Jan; 172(1): 142–
58.
39 Keppel Hesselink JM, Costagliola C, Fakhry J, 
Kopsky DJ. Palmitoylethanolamide, a natural 
retinoprotectant: its putative relevance for the 
treatment of glaucoma and diabetic retinopa-
thy. J Ophthalmol. 2015; 2015: 430596.
40 Caruso S, Iraci Sareri M, Casella E, Ventura B, 
Fava V, Cianci A. Chronic pelvic pain, quality 
of life and sexual health of women treated 
with palmitoylethanolamide and α-lipoic 
acid. Minerva Ginecol. 2015 Oct; 67(5): 413–9.
41 Del Giorno R, Skaper S, Paladini A, Varrassi 
G, Coaccioli S. Palmitoylethanolamide in Fi-
bromyalgia: Results from Prospective and 
Retrospective Observational Studies. Pain 
Ther. 2015 Dec; 4(2): 169–78.
42 Valdivia LF, Centurión D, Perusquía M, Arul-
mani U, Saxena PR, Villalón CM. Pharmaco-
logical analysis of the mechanisms involved in 
the tachycardic and vasopressor responses to 
the antimigraine agent, isometheptene, in 
pithed rats. Life Sci. 2004 May; 74(26): 3223–
34.
43 Gupta S, Villalón CM. The relevance of pre-
clinical research models for the development 
of antimigraine drugs: focus on 5-HT(1B/1D) 
and CGRP receptors. Pharmacol Ther. 2010 
Oct; 128(1): 170–90.
44 Bayne K. Revised guide for the care and use of 
laboratory animals. American Physiological 
Society. Physiologist. 1996 Aug; 39(4): 208–11.
45 McGrath JC, Drummond GB, McLachlan 
EM, Kilkenny C, Wainwright CL. Guidelines 
for reporting experiments involving animals: 
the ARRIVE guidelines. Br J Pharmacol. 2010 
Aug; 160(7): 1573–6.
46 Ryberg E, Larsson N, Sjögren S, Hjorth S, 
Hermansson NO, Leonova J, et al. The or-
phan receptor GPR55 is a novel cannabinoid 
receptor. Br J Pharmacol. 2007 Dec; 152(7): 
1092–101.
47 Katoch-Rouse R, Pavlova OA, Caulder T, 
Hoffman AF, Mukhin AG, Horti AG. Synthe-
sis, structure-activity relationship, and evalu-
ation of SR141716 analogues: development of 
central cannabinoid receptor ligands with 
lower lipophilicity. J Med Chem. 2003 Feb; 
46(4): 642–5.
48 Donohue SR, Halldin C, Pike VW. Synthesis 
and structure-activity relationships (SARs) of 
1,5-diarylpyrazole cannabinoid type-1 
(CB(1)) receptor ligands for potential use in 
molecular imaging. Bioorg Med Chem. 2006 
Jun; 14(11): 3712–20.
49 Ross RA, Brockie HC, Stevenson LA, Murphy 
VL, Templeton F, Makriyannis A, et al. Ago-
nist-inverse agonist characterization at CB1 
and CB2 cannabinoid receptors of L759633, 
L759656, and AM630. Br J Pharmacol. 1999 
Feb; 126(3): 665–72.
50 Ross RA, Gibson TM, Brockie HC, Leslie M, 
Pashmi G, Craib SJ, et al. Structure-activity 
relationship for the endogenous cannabinoid, 
anandamide, and certain of its analogues at 
vanilloid receptors in transfected cells and vas 
deferens. Br J Pharmacol. 2001 Feb; 132(3): 
631–40.
51 Thomas A, Baillie GL, Phillips AM, Razdan 
RK, Ross RA, Pertwee RG. Cannabidiol dis-
plays unexpectedly high potency as an antag-
onist of CB1 and CB2 receptor agonists in vi-
tro. Br J Pharmacol. 2007 Mar; 150(5): 613–
23.
D
ow
nl
oa
de
d 
by
: 
Er
as
m
us
 U
ni
ve
rs
ity
 R
ot
te
rd
am
15
4.
59
.1
24
.3
8 
- 4
/2
9/
20
20
 1
0:
43
:5
0 
AM
